The Neuroscience of Parkinson’s Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. The book also fills a much-needed gap as a "one-stop" synopsis of everything to do with the neurology and neuroscience related to Parkinson’s disease—from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. Contributors of volume 1 - p. v 7. Contributors of volume 2 - p. xiii 8. Foreword - p. xxiii 9. Preface of volume 1 - p. xxiv 10. Preface of volume 2 - p. xxv 11. Volume 1 - p. xxvi 12. Part I. Introductory chapters and setting the scene - p. xxvi 13. Chapter 1. Progression of symptoms in Parkinson's disease - p. xxvi 14. Chapter 2. Cellular pathophysiology and basal ganglia dysfunction in Parkinson's disease: an overview - p. xxvi 15. Chapter 3. The role of environmental toxins and inflammation in Parkinson's disease pathophysiology: a historical perspective and research-based evidence - p. xxvi 16. Chapter 4. Environmental and genetic risk factors for Parkinson's disease - p. 50 17. Chapter 5. Recent developments in the etiology, treatment, and potential therapeutic targets for Parkinson's disease: a focus on biochemistry - p. 50 18. Chapter 6. Facial emotion recognition in Parkinson's disease: methodological, clinical, and pathophysiological factors - p. 82 19. Chapter 7. Diurnal patterns and circadian aspects of Parkinson's disease: retinal, hypothalamic/midbrain, and pineal participation - p. 100 20. Chapter 8. Parkinson's disease and social media - p. 122 21. Chapter 9. Sleep disturbances in Parkinson's disease - p. 122 22. Chapter 10. Recurrent falls in people with Parkinson's disease - p. 122 23. Chapter 11. Medical decision-making in patients with Parkinson's disease - p. 174 24. Chapter 12. Visual impairment in Parkinson's disease - p. 174 25. Chapter 13. Autonomic problems in Parkinson's disease: a focus on the bladder - p. 204 26. Chapter 14. Dementia and bladder dysfunction: a focus on treatments with anticholinergics - p. 233 27. Chapter 15. Linking and comparing non-motor symptoms in aging and Parkinson's disease - p. 250 28. Chapter 16. Progression of motor symptoms in Parkinson's disease - p. 250 29. Chapter 17. The stigma of Parkinson's disease: development and implications - p. 250 30. Part II. Biomarkers, instruments, diagnosis and assessments - p. 250 31. Chapter 18. Better neuroradiological approach for the diagnosis of early-stage Parkinson's disease patients - p. 250 32. Chapter 19. Use of positron-emission tomography as a diagnostic and differential diagnostic tool in parkinsonian syndromes - p. 312 33. Chapter 20. Keyboard typing for the detection of early Parkinson's disease - p. 326 34. Chapter 21. Cerebrospinal fluid biomarkers of Parkinson's disease: an update - p. 344 35. Chapter 22. Understanding Parkinson's disease pathophysiology: clinical application of eye movement tasks and underlying neural correlates - p. 344 36. Chapter 23. Measuring quality of life in Parkinson's disease - p. 344 37. Chapter 24. Clinically assessing cognitive function in Parkinson's disease - p. 394 38. Part III. Pharmacological treatments, other agents and strategies - p. 394 39. Chapter 25. A new neuroprotective strategy for the drug therapy of Parkinson's disease: Ca2+/cAMP signaling as therapeutic targets - p. 394 40. Chapter 26. Dopamine agonists in treatment of Parkinson's disease: an overview - p. 394 41. Chapter 27. Management with apomorphine in Parkinson's disease - p. 394 42. Chapter 28. Management with monoamine oxidase B inhibitors in Parkinson's disease - p. 394 43. Chapter 29. Management with antibiotics in Parkinson's disease - p. 478 44. Chapter 30. Intracerebroventricular administration of dopamine in Parkinson's disease: treatment of motor fluctuations and dyskinesia - p. 510 45. Chapter 31. Placebo and nocebo responses in Parkinson's disease - p. 510 46. Chapter 32. Levodopa-induced dyskinesias in Parkinson's disease - p. 538 47. Chapter 33. Cannabinoid receptor type 2 as a therapeutic target for Parkinson's disease - p. 554 48. Part IV. Non-pharmacological, novel and other treatment procedures - p. 554 49. Chapter 34. Deep brain stimulation surgery in Parkinson's disease - p. 554 50. Chapter 35. Gene delivery for Parkinson's disease - p. 596 51. Chapter 36. Cell transplantation therapy for Parkinson's disease - p. 625 52. Chapter 37. Ursodeoxycholic and tauroursodeoxycholic acids as antiapoptotic agents: modulation of Parkinson's disease - p. 625 53. Chapter 38. Interlinking potential therapy with botulinum neurotoxin-A and Parkinson's disease - p. 662 54. Chapter 39. Neuropeptide cocaine- and amphetamine-regulated transcript usage in Parkinson's disease - p. 662 55. Chapter 40. Photobiomodulation as a neuroprotective strategy for Parkinson's disease - p. 688 56. Chapter 41. Assistive technologies in Parkinson's disease - p. 688 57. Chapter 45. Neuroscience of Parkinson's disease: recommended reading and resources - p. 703 58. Volume 2 - p. 710 59. Chapter 1. Leucine-rich repeat kinase 2 (LRRK2) and Parkinson's disease: from genetics to pathobiology - p. 3 60. Chapter 2. Alpha-synuclein gene and Parkinson's disease - p. 19 61. Chapter 3. The DJ-1 gene and protein: links with Parkinson's disease - p. 35 62. Chapter 4. Regulation of tyrosine hydroxylase: relevance to Parkinson's disease - p. 51 63. Chapter 5. Linking glucocerebrosidase gene (GBA) variants and Parkinson's disease - p. 67 64. Chapter 6. Astrocytes and microglia in Parkinson's disease and animal models - p. 83 65. Chapter 7. The role of autophagy in Parkinson's disease etiopathogenesis - p. 101 66. Chapter 8. The mitochondrial network in Parkinson's disease - p. 123 67. Chapter 9. Signal transduction in Parkinson's disease: modulation of neurotransmission, symptomatology, and therapy - p. 139 68. Chapter 10. Oxidative stress signaling and regulated cell death in Parkinson's disease - p. 157 69. Chapter 11. Subcellular-specific alpha-synuclein in Parkinson's disease - p. 175 70. Chapter 12. Melanocortin 1 receptor: Parkinson's disease, melanoma risk, and neuroprotection - p. 189 71. Chapter 13. Energy regulation and Parkinson's disease - p. 205 72. Chapter 14. Linking rotigotine, Parkinson's disease, and brain-derived neurotrophic factor - p. 221 73. Part II. Neurology, physiology and imaging - p. 232 74. Chapter 15. The different syndromes in Parkinson's disease: an overview - p. 235 75. Chapter 16. Neuromolecular imaging in Parkinson's disease - p. 251 76. Chapter 17. Interlinking brain mapping and Parkinson's disease: MRI analysis, nigrosome 1 and nigrosome 4 - p. 267 77. Chapter 18. Interconnecting Parkinson's disease: the use of computed tomography and microelectrode recording in DBS surgery - p. 283 78. Chapter 19. Linking diffusion tensor imaging, microstructures and Parkinson's disease - p. 295 79. Chapter 20. Detecting parkinsonian degeneration in lateroventral tier of substantia nigra pars compacta with MRI - p. 313 80. Chapter 21. Vagal motoneurons in Parkinson's disease - p. 327 81. Chapter 22. Circadian clock disruption and neuroinflammation in Parkinson's disease: a new perspective - p. 345 82. Chapter 23. Motor cortex stimulation in Parkinson's disease - p. 363 83. Chapter 24. Action programming disorders associated with Parkinson's disease - p. 377 84. Chapter 25. The striatal medium spiny neurons: what they are and how they link with Parkinson's disease - p. 395 85. Chapter 26. Disruptions of frontostriatal language functions in Parkinson's disease - p. 413 86. Chapter 27. Alpha-synuclein and neuroinflammation in Parkinson's disease - p. 431 87. Chapter 28. Tau and its interactions with other proteins in neurodegenerative diseases - p. 447 88. Chapter 29. Interaction between brain angiotensin and dopaminergic systems and Parkinson's disease - p. 463 89. Chapter 30. Restoring dopamine levels in Parkinson's disease: neuronal pathways, agonists and antiinflammatory agents - p. 479 90. Part III. Behaviour and psychopathology - p. 493 91. Chapter 31. Motivation and motivational aspects of Parkinson's disease - p. 497 92. Chapter 32. Linking anxiety, cognitive and sensory deficits to gait and balance deficits in Parkinson's disease - p. 511 93. Chapter 33. Motor programs interlinking gait and bradykinesia in Parkinson's disease - p. 521 94. Chapter 34. Olfactory disturbances in Parkinson’s disease - p. 539 95. Part IV. Diet and nutrition - p. 552 96. Chapter 35. Interlinking dementia in Parkinson's disease: nutritional correlates of body composition - p. 555 97. Chapter 36. The role of the gastrointestinal system and gut microbiota in Parkinson's disease - p. 569 98. Chapter 37. Swallowing impairment in Parkinson's disease - p. 583 99. Chapter 38. The Mini Nutritional Assessment (MNA) and applications to Parkinson's disease - p. 597 100. Chapter 39. The efficacy of Bacopa monnieri extract in modulating Parkinson's disease - p. 609 101. Part V. Models, modelling and resources - p. 624 102. Chapter 40. 6-hydroxydopamine-induced model of Parkinson's disease - p. 627 103. Chapter 41. Knockdown transgenic Drosophila and Parkinson's disease - p. 643 104. Chapter 42. Neuroprotection in animal models of Parkinson's disease: exploring exercise, sound, and light - p. 663 105. Chapter 43. Modeling with the A53T α-synuclein model of Parkinson's disease - p. 677 106. Chapter 44. Linking the leucine-rich repeat kinase 2 gene, animal models, and Parkinson's disease - p. 689 107. Index - p. 702 108. Index - p. 711
The Neuroscience of Parkinson’s Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. The book also fills a much-needed gap as a "one-stop" synopsis of everything to do with the neurology and neuroscience related to Parkinson’s disease—from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. Contributors of volume 1 - p. v 7. Contributors of volume 2 - p. xiii 8. Foreword - p. xxiii 9. Preface of volume 1 - p. xxiv 10. Preface of volume 2 - p. xxv 11. Volume 1 - p. xxvi 12. Part I. Introductory chapters and setting the scene - p. xxvi 13. Chapter 1. Progression of symptoms in Parkinson's disease - p. xxvi 14. Chapter 2. Cellular pathophysiology and basal ganglia dysfunction in Parkinson's disease: an overview - p. xxvi 15. Chapter 3. The role of environmental toxins and inflammation in Parkinson's disease pathophysiology: a historical perspective and research-based evidence - p. xxvi 16. Chapter 4. Environmental and genetic risk factors for Parkinson's disease - p. 50 17. Chapter 5. Recent developments in the etiology, treatment, and potential therapeutic targets for Parkinson's disease: a focus on biochemistry - p. 50 18. Chapter 6. Facial emotion recognition in Parkinson's disease: methodological, clinical, and pathophysiological factors - p. 82 19. Chapter 7. Diurnal patterns and circadian aspects of Parkinson's disease: retinal, hypothalamic/midbrain, and pineal participation - p. 100 20. Chapter 8. Parkinson's disease and social media - p. 122 21. Chapter 9. Sleep disturbances in Parkinson's disease - p. 122 22. Chapter 10. Recurrent falls in people with Parkinson's disease - p. 122 23. Chapter 11. Medical decision-making in patients with Parkinson's disease - p. 174 24. Chapter 12. Visual impairment in Parkinson's disease - p. 174 25. Chapter 13. Autonomic problems in Parkinson's disease: a focus on the bladder - p. 204 26. Chapter 14. Dementia and bladder dysfunction: a focus on treatments with anticholinergics - p. 233 27. Chapter 15. Linking and comparing non-motor symptoms in aging and Parkinson's disease - p. 250 28. Chapter 16. Progression of motor symptoms in Parkinson's disease - p. 250 29. Chapter 17. The stigma of Parkinson's disease: development and implications - p. 250 30. Part II. Biomarkers, instruments, diagnosis and assessments - p. 250 31. Chapter 18. Better neuroradiological approach for the diagnosis of early-stage Parkinson's disease patients - p. 250 32. Chapter 19. Use of positron-emission tomography as a diagnostic and differential diagnostic tool in parkinsonian syndromes - p. 312 33. Chapter 20. Keyboard typing for the detection of early Parkinson's disease - p. 326 34. Chapter 21. Cerebrospinal fluid biomarkers of Parkinson's disease: an update - p. 344 35. Chapter 22. Understanding Parkinson's disease pathophysiology: clinical application of eye movement tasks and underlying neural correlates - p. 344 36. Chapter 23. Measuring quality of life in Parkinson's disease - p. 344 37. Chapter 24. Clinically assessing cognitive function in Parkinson's disease - p. 394 38. Part III. Pharmacological treatments, other agents and strategies - p. 394 39. Chapter 25. A new neuroprotective strategy for the drug therapy of Parkinson's disease: Ca2+/cAMP signaling as therapeutic targets - p. 394 40. Chapter 26. Dopamine agonists in treatment of Parkinson's disease: an overview - p. 394 41. Chapter 27. Management with apomorphine in Parkinson's disease - p. 394 42. Chapter 28. Management with monoamine oxidase B inhibitors in Parkinson's disease - p. 394 43. Chapter 29. Management with antibiotics in Parkinson's disease - p. 478 44. Chapter 30. Intracerebroventricular administration of dopamine in Parkinson's disease: treatment of motor fluctuations and dyskinesia - p. 510 45. Chapter 31. Placebo and nocebo responses in Parkinson's disease - p. 510 46. Chapter 32. Levodopa-induced dyskinesias in Parkinson's disease - p. 538 47. Chapter 33. Cannabinoid receptor type 2 as a therapeutic target for Parkinson's disease - p. 554 48. Part IV. Non-pharmacological, novel and other treatment procedures - p. 554 49. Chapter 34. Deep brain stimulation surgery in Parkinson's disease - p. 554 50. Chapter 35. Gene delivery for Parkinson's disease - p. 596 51. Chapter 36. Cell transplantation therapy for Parkinson's disease - p. 625 52. Chapter 37. Ursodeoxycholic and tauroursodeoxycholic acids as antiapoptotic agents: modulation of Parkinson's disease - p. 625 53. Chapter 38. Interlinking potential therapy with botulinum neurotoxin-A and Parkinson's disease - p. 662 54. Chapter 39. Neuropeptide cocaine- and amphetamine-regulated transcript usage in Parkinson's disease - p. 662 55. Chapter 40. Photobiomodulation as a neuroprotective strategy for Parkinson's disease - p. 688 56. Chapter 41. Assistive technologies in Parkinson's disease - p. 688 57. Chapter 45. Neuroscience of Parkinson's disease: recommended reading and resources - p. 703 58. Volume 2 - p. 710 59. Chapter 1. Leucine-rich repeat kinase 2 (LRRK2) and Parkinson's disease: from genetics to pathobiology - p. 3 60. Chapter 2. Alpha-synuclein gene and Parkinson's disease - p. 19 61. Chapter 3. The DJ-1 gene and protein: links with Parkinson's disease - p. 35 62. Chapter 4. Regulation of tyrosine hydroxylase: relevance to Parkinson's disease - p. 51 63. Chapter 5. Linking glucocerebrosidase gene (GBA) variants and Parkinson's disease - p. 67 64. Chapter 6. Astrocytes and microglia in Parkinson's disease and animal models - p. 83 65. Chapter 7. The role of autophagy in Parkinson's disease etiopathogenesis - p. 101 66. Chapter 8. The mitochondrial network in Parkinson's disease - p. 123 67. Chapter 9. Signal transduction in Parkinson's disease: modulation of neurotransmission, symptomatology, and therapy - p. 139 68. Chapter 10. Oxidative stress signaling and regulated cell death in Parkinson's disease - p. 157 69. Chapter 11. Subcellular-specific alpha-synuclein in Parkinson's disease - p. 175 70. Chapter 12. Melanocortin 1 receptor: Parkinson's disease, melanoma risk, and neuroprotection - p. 189 71. Chapter 13. Energy regulation and Parkinson's disease - p. 205 72. Chapter 14. Linking rotigotine, Parkinson's disease, and brain-derived neurotrophic factor - p. 221 73. Part II. Neurology, physiology and imaging - p. 232 74. Chapter 15. The different syndromes in Parkinson's disease: an overview - p. 235 75. Chapter 16. Neuromolecular imaging in Parkinson's disease - p. 251 76. Chapter 17. Interlinking brain mapping and Parkinson's disease: MRI analysis, nigrosome 1 and nigrosome 4 - p. 267 77. Chapter 18. Interconnecting Parkinson's disease: the use of computed tomography and microelectrode recording in DBS surgery - p. 283 78. Chapter 19. Linking diffusion tensor imaging, microstructures and Parkinson's disease - p. 295 79. Chapter 20. Detecting parkinsonian degeneration in lateroventral tier of substantia nigra pars compacta with MRI - p. 313 80. Chapter 21. Vagal motoneurons in Parkinson's disease - p. 327 81. Chapter 22. Circadian clock disruption and neuroinflammation in Parkinson's disease: a new perspective - p. 345 82. Chapter 23. Motor cortex stimulation in Parkinson's disease - p. 363 83. Chapter 24. Action programming disorders associated with Parkinson's disease - p. 377 84. Chapter 25. The striatal medium spiny neurons: what they are and how they link with Parkinson's disease - p. 395 85. Chapter 26. Disruptions of frontostriatal language functions in Parkinson's disease - p. 413 86. Chapter 27. Alpha-synuclein and neuroinflammation in Parkinson's disease - p. 431 87. Chapter 28. Tau and its interactions with other proteins in neurodegenerative diseases - p. 447 88. Chapter 29. Interaction between brain angiotensin and dopaminergic systems and Parkinson's disease - p. 463 89. Chapter 30. Restoring dopamine levels in Parkinson's disease: neuronal pathways, agonists and antiinflammatory agents - p. 479 90. Part III. Behaviour and psychopathology - p. 493 91. Chapter 31. Motivation and motivational aspects of Parkinson's disease - p. 497 92. Chapter 32. Linking anxiety, cognitive and sensory deficits to gait and balance deficits in Parkinson's disease - p. 511 93. Chapter 33. Motor programs interlinking gait and bradykinesia in Parkinson's disease - p. 521 94. Chapter 34. Olfactory disturbances in Parkinson’s disease - p. 539 95. Part IV. Diet and nutrition - p. 552 96. Chapter 35. Interlinking dementia in Parkinson's disease: nutritional correlates of body composition - p. 555 97. Chapter 36. The role of the gastrointestinal system and gut microbiota in Parkinson's disease - p. 569 98. Chapter 37. Swallowing impairment in Parkinson's disease - p. 583 99. Chapter 38. The Mini Nutritional Assessment (MNA) and applications to Parkinson's disease - p. 597 100. Chapter 39. The efficacy of Bacopa monnieri extract in modulating Parkinson's disease - p. 609 101. Part V. Models, modelling and resources - p. 624 102. Chapter 40. 6-hydroxydopamine-induced model of Parkinson's disease - p. 627 103. Chapter 41. Knockdown transgenic Drosophila and Parkinson's disease - p. 643 104. Chapter 42. Neuroprotection in animal models of Parkinson's disease: exploring exercise, sound, and light - p. 663 105. Chapter 43. Modeling with the A53T α-synuclein model of Parkinson's disease - p. 677 106. Chapter 44. Linking the leucine-rich repeat kinase 2 gene, animal models, and Parkinson's disease - p. 689 107. Index - p. 702 108. Index - p. 711
